Medpace Holdings, Inc.
NASDAQ:MEDP · NASDAQ Global Select
-$4.51 today
Vol 0.43M · Avg 0.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
98.3%
avg 30.2%
ROIC
67.9%
avg 22.9%
ROA
22.8%
avg 10.9%
Analysis
ROE is currently the strongest return metric at 98.3% versus its period average of 30.2%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
August James Troendle | CEO, President & Chairman | $1.44M | — | 70 | $20,000.00 | 0.07% |
Susan E. Burwig | Executive Vice President of Operations | $1.22M | — | 63 | $10,000.00 | 0.04% |
Brad W. Hansman | Executive Vice President of Operations | $1.22M | — | 43 | $0.00 | <0.01% |
Stephen Ewald | Chief Compliance Officer, General Counsel & Corporate Secretary | $1.02M | — | 57 | $36,692.00 | 0.13% |
Jesse J. Geiger | President | $896,367.00 | — | 52 | $20,000.00 | 0.07% |
Kevin Brady | Chief Financial Officer & Treasurer | $646,145.00 | — | 51 | $12,830.00 | 0.04% |
Lauren Morris | Associate Director of Investors Relations | — | — | — | — | — |
Brandon Ebken | Chief Information Officer | — | — | — | — | — |
John T. Wynne | Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | — | — | — | — | — |
Todd Meyers | Vice President of Business Development & Marketing | — | — | — | — | — |
Weimin Gai | Senior Vice President of Biometrics | — | — | — | — | — |
Gina Leisring | Senior Vice President of Clinical Monitoring | — | — | — | — | — |
Reinilde Heyrman | Chief Medical Officer of Medical Department | — | — | 65 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
37
$333.22M
Net Sentiment
$333.22M
Net selling
Most Active
Troendle August J.
19 transactions
1–10 of 37
Analysis
Insiders reported 0 buys worth $0.00 and 37 sells worth $333.22M over the last 12 months. That adds up to net selling of $333.22M. Troendle August J. was the most active insider with 19 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +27.9% (13yr)3 analysts |
| Revenue | N/A | N/A | +14.6% | +17.9% (13yr)4 analysts |
| Net Income | N/A | N/A | N/A | +25.0% (13yr)4 analysts |
| EBIT | N/A | N/A | +35.6% | +23.3% (13yr)4 analysts |
Analysis
Recent growth has been strongest in EBIT at +35.6% over three years. Forward estimates point to EPS at +27.9% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centene Corporation
NYSE:CNC
$29.94B
Illumina, Inc.
NASDAQ:ILMN
$24.07B
Waters Corporation
NYSE:WAT
$23.27B
West Pharmaceutical Services, Inc.
NYSE:WST
$22.86B
Quest Diagnostics Incorporated
NYSE:DGX
$21.89B
Hologic, Inc.
HOLX
$16.97B
Tenet Healthcare Corporation
NYSE:THC
$15.38B
Smith & Nephew plc
NYSE:SNN
$12.74B
ICON Public Limited Company
NASDAQ:ICLR
$10.97B
Tempus AI, Inc.
NASDAQ:TEM
$8.51B
Who manages MEDP?
Medpace Holdings, Inc. (MEDP) lists 13 active executives. The top listed executive is Stephen Ewald, Chief Compliance Officer, General Counsel & Corporate Secretary.
Are MEDP insiders buying or selling?
Recent insider activity shows net selling of $265.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.